PBH Prestige Consumer Healthcare Inc

Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder Due to the Presence of Benzene

Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder Due to the Presence of Benzene

TARRYTOWN, N.Y., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily recalling two lots of TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder to the consumer level. A recent review by our manufacturer and their third-party lab found that samples from two lots of the product contained elevated levels of benzene. While benzene is not an ingredient in any Ting® Antifungal Spray products, the review showed that unexpected levels of benzene came from the propellant that sprays the product out of the can. Importantly, no other lots of TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder (either before or after these batch codes) and no other Ting® Antifungal Spray products are in the scope of this recall and may continue to be used by consumers safely and as intended.

Risk Statement: Benzene is classified as a human carcinogen. Exposure to benzene can occur by inhalation, orally, and through the skin and it potentially can result in cancers including leukemia and blood cancer of the bone marrow and blood disorders which can be life threatening. Insight is recalling these products out of an abundance of caution. To date, the Company has not received any serious adverse events related to this recall. Benzene is ubiquitous in the environment. Humans around the world have daily exposures to it indoors and outdoors from multiple sources.

TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder is packaged in green and white aerosol cans with Lot codes located on the bottom of the can.



Samples of the recalled lots below have been found to contain trace levels of Benzene related to the propellant that sprays the product out of the can. Benzene is not an ingredient in any Ting products.

 Product NDC Lot Code Expiration Package Size
 TING 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder 63736-532-05 0H88645 07/24 4.5 oz/128 g
 TING 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder 63736-532-05 0B88345 02/24 4.5 oz/128 g
 

The affected TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder lots were distributed nationwide in the United States through a limited number of retailers and online.

Insight has notified retailers via overnight mail to remove any remaining recalled product from shelves and follow the instructions provided in the Drug Recall Notification. The company will also offer reimbursement for consumers who have purchased TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray marked with one of the lot codes in the table above. Consumers can contact Insight Pharmaceuticals via e-mail at , through its website at , or by phone at (800) 344-7239 on Monday – Friday 8:30-5:30 eastern time to receive a full refund by providing a picture of the bottom of the can of the TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray with the affected lot number. Consumers that have product which is being recalled should stop using the product immediately and appropriately discard after taking the picture.

No serious adverse events have been reported to date.

Consumers with questions regarding this recall can contact Insight Pharmaceuticals via e-mail at , through its website at , or by phone at (800) 344-7239 on Monday – Friday 8:30-5:30 eastern time. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this antifungal product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Complete and submit the report Online:
  • Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

A photo accompanying this announcement is available at



Investor Relations Contact
Phil Terpolilli, CFA, 914-524-6819
 
EN
24/11/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Prestige Consumer Healthcare Inc

 PRESS RELEASE

Prestige Consumer Healthcare Inc. Reports Third Quarter and Year-to-Da...

Prestige Consumer Healthcare Inc. Reports Third Quarter and Year-to-Date Fiscal 2026 Results Revenue of $283.4 million in Q3, ahead of outlookDiluted EPS of $0.97 in Q3 and Adjusted Diluted EPS of $1.14, versus prior year Q3 Diluted EPS of $1.22Repurchased approximately 0.8 million shares opportunistically in Q3Successfully closed acquisition of eye care supplier Pillar5 Pharma, Inc. in December, as expectedNarrowing Outlook Range of Fiscal 2026 Revenue and Adjusted Diluted EPS TARRYTOWN, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today rep...

 PRESS RELEASE

Prestige Consumer Healthcare Announces Fiscal 2026 Third Quarter Earni...

Prestige Consumer Healthcare Announces Fiscal 2026 Third Quarter Earnings Results Date and Participation in the ICR Conference TARRYTOWN, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (the “Company” or “Prestige”) (NYSE: PBH) today announced it will issue its fiscal 2026 third quarter earnings release on Thursday, February 5, 2026 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.   To participate in the live Internet webcast of the conference call, it can be accessed from the Inv...

 PRESS RELEASE

Prestige Consumer Healthcare Inc. Reports Second Quarter and First Hal...

Prestige Consumer Healthcare Inc. Reports Second Quarter and First Half Fiscal 2026 Results Revenue of $274.1 million in Q2, ahead of outlookDiluted EPS of $0.86 in Q2 and Adjusted Diluted EPS of $1.07, versus prior year Q2 Diluted EPS of $1.09Repurchased approximately 1.1 million shares opportunistically in Q2Fiscal 2026 revenue outlook unchanged; Adjusted Diluted EPS outlook updated to $4.54 to $4.58, high end of previous range TARRYTOWN, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and firs...

 PRESS RELEASE

Prestige Consumer Healthcare to Release Fiscal 2026 Second Quarter Ear...

Prestige Consumer Healthcare to Release Fiscal 2026 Second Quarter Earnings Results TARRYTOWN, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 second quarter and first half earnings release on Thursday, November 6, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of . To participate in the confere...

 PRESS RELEASE

Prestige Consumer Healthcare to Present at the Barclays Global Consume...

Prestige Consumer Healthcare to Present at the Barclays Global Consumer Staples Conference TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced it will present at the Barclays Global Consumer Staples Conference on Thursday, September 4, 2025 at 12:45 p.m. ET. All interested parties may access a live webcast of this event at under the “Investors” section and the “Events and Presentations” tab, or by using the following link: For those unable to participate during the live webcast, a replay option will be available on the C...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch